Kwaśniewska A, Goździcka-Józefiak A, Postawski K, Miturski R
I Clinic of Obstetrics and Gynaecology, Lublin Medical Academy, Poland.
Eur J Gynaecol Oncol. 2002;23(3):231-5.
The aim of this study was to answer the question whether the products of hMSH2 and hMLH1 genes take part in the mutation track of cervical carcinoma.
IgG1 monoclonal antibodies (Pharmingen) detecting epitopes characteristic of hMLH1 and hMSH2 were used in the present study. The value of the half-quantitative H-score coefficient was calculated. Its threshold value was 0.4. Identification of 16 and 18 HPV types was performed by PCR.
An intensified hMLH1 protein expression was observed both in the squamous epithelial carcinomas and cervical adenocarcinomas (H-score of 1.44 and 0.98, respectively) as compared to the control (H-score of 0.9). However, a decreased expression of hMSH2 protein was observed in the analysed cases of carcinoma (0.9 and 0.7) as compared to the control group (1.2). An intensified expression in G3 for hMLH1 and higher hMLH1 in comparison to hMSH2 was observed.
本研究的目的是回答人源错配修复蛋白2(hMSH2)和人源错配修复蛋白1(hMLH1)基因产物是否参与宫颈癌的突变轨迹这一问题。
本研究使用了检测hMLH1和hMSH2表位特征的IgG1单克隆抗体(Pharmingen公司)。计算半定量H评分系数的值。其阈值为0.4。通过聚合酶链反应(PCR)鉴定16型和18型人乳头瘤病毒(HPV)。
与对照组(H评分为0.9)相比,在鳞状上皮癌和宫颈腺癌中均观察到hMLH1蛋白表达增强(分别为1.44和0.98)。然而,与对照组(1.2)相比,在分析的癌病例中观察到hMSH2蛋白表达降低(0.9和0.7)。观察到hMLH1在G3中的表达增强,且hMLH1相对于hMSH2表达更高。